Pulmonx released positive one-year-results from the LIBERATE pivotal trial of the Zephyr Endobronchial Valve, which shows the study met all primary and secondary endpoints.
If the Amplatzer Amulet Left Atrial Appendage (LAA) occlusion device gains approval in the U.S., the device could go head-to-head with Boston Scientific’s Watchman.
Freenome has initiated a clinical study to help bring an AI-Genomics blood test for colorectal cancer to the U.S. market.
Grail raises $300 million in Series C round to give massive boost to the development of its liquid biopsy applications for cancer.
Beta Bionics receives IDE approval from FDA to begin a clinical trial testing the iLet Bionic Pancreas System.
TAVR pioneer Edwards Lifesciences has released positive 30-day data of its Sapien 3 valve at EuroPCR.
Blue Earth Diagnostics’ LOCATE clinical study shows 59% of patients with suspected recurrent prostate cancer had a change in their management plan following an 18F fluciclovine PET/CT scan.
Johnson & Johnson’s Cerenovus has stiff competition in the stent retriever market from both Stryker and Medtronic.
The Department of Homeland Security has warned in a report that there are cybersecurity vulnerabilities in Medtronic’s N’Vision clinical programmer.
StimGuard scores a CE mark for its overactive bladder system and becomes the latest company to have a commercialized product in the neuromodulation space.
LifePlus, which has been in stealth mode until now, is developing Lifeleaf, a non-invasive continuous blood glucose monitoring (CGM) multi-sensor wearable device.
Medtronic has initiated a clinical study to see if its Resolute Onyx DES can treat bifurcation lesions, which account for about 20% of all percutaneous coronary interventions.